These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25602797)

  • 1. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.
    Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM
    Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
    Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
    Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis.
    Kim JY; Kim KS; Kim KJ; Park IJ; Lee JL; Myung SJ; Park Y; Park YS; Yu CS; Kim JC; Yu E; Jang HJ; Hong SM
    Am J Surg Pathol; 2015 May; 39(5):632-43. PubMed ID: 25724002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
    Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
    Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
    Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
    Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
    Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 12. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
    Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
    Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
    JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors.
    Son EM; Kim JY; An S; Song KB; Kim SC; Yu E; Hong SM
    J Pathol Transl Med; 2015 Jan; 49(1):30-6. PubMed ID: 25812655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.